Allogene Therapeutics (ALLO) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Allogene Therapeutics is set to release its earnings on August 6th, with analysts predicting a loss of ($0.28) per share for the quarter.
• The company's stock has declined by 4.8%, currently trading at $1.40, with a market cap of $306.22 million.
• Research analysts have recently lowered their price targets for Allogene Therapeutics, with the average target now at $8.44, but the consensus remains a "Moderate Buy."

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) is expected to release its earnings data before the market opens on Wednesday, August 6th. Analysts expect Allogene Therapeutics to post earnings of ($0.28) per share for the quarter.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28). On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Trading Down 12.2%

ALLO traded down $0.15 during trading on Friday, hitting $1.08. 19,087,454 shares of the company traded hands, compared to its average volume of 4,806,039. The company has a market cap of $236.23 million, a PE ratio of -0.88 and a beta of 0.35. Allogene Therapeutics has a 1 year low of $0.86 and a 1 year high of $3.78. The stock's 50-day simple moving average is $1.28 and its two-hundred day simple moving average is $1.51.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ALLO. AQR Capital Management LLC acquired a new stake in shares of Allogene Therapeutics during the first quarter worth about $85,000. Jane Street Group LLC boosted its position in shares of Allogene Therapeutics by 578.7% during the 1st quarter. Jane Street Group LLC now owns 1,116,681 shares of the company's stock worth $1,630,000 after purchasing an additional 952,158 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company's stock valued at $8,547,000 after buying an additional 3,747,397 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ALLO. Oppenheimer lowered their target price on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating for the company in a report on Wednesday, May 14th. Piper Sandler lowered their target price on shares of Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Citizens Jmp downgraded shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 14th. Truist Financial reduced their price target on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Robert W. Baird reduced their price target on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.44.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).